Primary Immunodeficiency Diseases Market

Primary Immunodeficiency Diseases Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032

6.5%

CAGR (2026-2032)

2.99 USD Bn.

Market Size

324

Report Pages

144

Market Tables

Overview

The Primary Immunodeficiency Diseases Market size was valued at USD 2.99 Billion in 2025 and the total Primary Immunodeficiency Diseases revenue is expected to grow at a CAGR of 6.5% from 2025 to 2032, reaching nearly USD 4.65 Billion by 2032.

Primary Immunodeficiency Diseases Market Drivers and Restrains

Primary immunodeficiencies are disorders in which part of the body's immune system is missing or does not function normally. To be considered a primary immunodeficiency (PID), the cause of the immune deficiency must not be secondary in nature (i.e., caused by other disease, drug treatment, or environmental exposure to toxins). Most primary immunodeficiencies are genetic disorders; the majority are diagnosed in children under the age of one, although milder forms may not be recognized until adulthood. Rising prevalence of diseases such as selective IgA deficiency, and IgG subclass deficiency worldwide is fueling the Global Primary Immunodeficiency Diseases Market .The side-effects such as renal failure and allergic reactions associated with the treatment could hamper the Global Primary Immunodeficiency Diseases Market during forecast period. High-cost of the therapies is considered to be major restraint for global market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
To know about the Research Methodology :- Request Free Sample Report

Primary Immunodeficiency Diseases Market key segmentation

Global Primary Immunodeficiency Diseases Market is segmented by Disease, Test and Treatment. Based on disease the market is divided in to Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorders. Antibody Deficiency is further sub-divided into Agammaglobulinaemia (X-Linked and Autosomal Recessive), Common Variable Immune Deficiency, Selective IgA Deficiency IgG Subclass Deficiency and Others. Cellular Immunodeficiency is further categorized into Ataxia Telangiectasia, Hyper IgM Syndromes, Wiskott - Aldrich syndrome, DiGeorge Syndrome and Others. And Innate Immune Disorders is further segmented in to Complement Deficiencies, Hyper IgE Syndrome and Others. Among these, Cellular Immunodeficiency segment is expected to have market share of XX% during the forecast period because of rising patient population with this disease. By treatment the market is divided into Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem cell and Gene Therapy and Others. Among these Antibiotic therapy is expected share global market with XX%. There is no therapy that completely cures this disease thus, the goal is to prevent infections and improve quality of life using novel medications.

Primary Immunodeficiency Diseases Market Regional Analysis

Based on region the Global Primary Immunodeficiency Diseases Market is segmented into Asia Pacific, North America, Europe, Latin America and Middle East Africa. North America holds the highest share of Global Primary Immunodeficiency Diseases Market during forecast period. Increasing prevalence of diseases such as selective IgA deficiency, IgG subclass deficiency, and common variable immune deficiency has been witnessed in North America. In Europe, the market is expected have significant share of global market thanks to the increasing awareness regarding PIDD and favorable government support. The presence of companies such as Baxter International Inc., CSL Behring LLC, and Blotest Pharmaceuticals Corporation also supports the market’s expansion in the region. Asia-pacific is expected to grow with moderate CAGR of xx% during forecast period. The increasing willingness among people to spend on novel therapeutics fuels the global market in Asia Pacific.

The objective of the report is to present comprehensive analysis of Global Primary Immunodeficiency Diseases Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Primary Immunodeficiency Diseases Market dynamics, structure by analyzing the market segments, and project the Global Primary Immunodeficiency Diseases Market size. Clear representation of competitive analysis of key players by Primary Immunodeficiency Diseases Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Primary Immunodeficiency Diseases Market make the report investor’s guide.

Primary Immunodeficiency Diseases Market Scope: Inquire before buying

Global Primary Immunodeficiency Diseases Market
Report Coverage	Details
Base Year:	2025	Forecast Period:	2026-2032
Historical Data:	2020 to 2025	Market Size in 2025:	USD 2.99 Bn.
Forecast Period 2026 to 2032 CAGR:	6.5%	Market Size in 2032:	USD 4.65 Bn.
Segments Covered:	by Disease	Antibody Deficiency Cellular Immunodeficiency Innate Immune Disorder
	by Test	Blood Test Prenatal Testing
	by Treatment	Immunoglobulin Replacement Therapy Antibiotic Therapy Stem cell and Gene Therapy Others

Primary Immunodeficiency Diseases Market, by region

North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)

Primary Immunodeficiency Diseases Market, Key players are:

1. Baxter International, Inc.,
2. Biotest AG,
3. CSL Behring LLC,
4. Bio Products Laboratory Ltd.,
5. Kedrion S.p.A.,
6. LFB S.A.,
7. Octapharma AG
8. Grifols S.A
9. Abbott,
10. ADMA Biologics,
11. Astellas,
12. AstraZeneca,
13. Bayer,
14. Biocon,
15. Bristol-Myers Squibb,
16. BDI Pharma,
17. Bharat Serums and Vaccines,
18. Eli Lilly,
19. GlaxoSmithKline,
20. Hualan Biological Engineering,
21. Kedrion Biopharma,
22. Lupin Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global Primary Immunodeficiency Diseases Market?
Ans: North America region held the highest share in 2025.

2. What is the growth rate of Global Primary Immunodeficiency Diseases Market?
Ans: The Global Primary Immunodeficiency Diseases Market is growing at a CAGR of 6.5 % during forecasting period 2026-2032.

3. What is scope of the Global Primary Immunodeficiency Diseases market report?
Ans: Global Primary Immunodeficiency Diseases Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Primary Immunodeficiency Diseases market?
Ans: The important key players in the Global Primary Immunodeficiency Diseases Market are – Baxter International, Inc.,, Biotest AG,, CSL Behring LLC,, Bio Products Laboratory Ltd.,, Kedrion S.p.A.,, LFB S.A.,, Octapharma AG, Grifols S.A, Abbott,, ADMA Biologics,, Astellas,, AstraZeneca,, Bayer,, Biocon,, Bristol-Myers Squibb,, BDI Pharma,, Bharat Serums and Vaccines,, Eli Lilly,, GlaxoSmithKline,, Hualan Biological Engineering,, Kedrion Biopharma,, Lupin Pharmaceuticals, and

5. What is the study period of this market?
Ans: The Global Primary Immunodeficiency Diseases Market is studied from 2025 to 2032.

Global Primary Immunodeficiency Diseases Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Primary Immunodeficiency Diseases Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Primary Immunodeficiency Diseases Market Analysis and Forecast 6.1. Global Primary Immunodeficiency Diseases Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Primary Immunodeficiency Diseases Market Analysis and Forecast, by Treatment 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment 7.4. Global Primary Immunodeficiency Diseases Market Size (US$ Bn) Forecast, by Treatment 7.5. Global Primary Immunodeficiency Diseases Market Analysis, by Treatment 7.6. Global Primary Immunodeficiency Diseases Market Attractiveness Analysis, by Treatment 8. Global Primary Immunodeficiency Diseases Market Analysis and Forecast, by Test 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Primary Immunodeficiency Diseases Market Value Share Analysis, by Test 8.4. Global Primary Immunodeficiency Diseases Market Size (US$ Bn) Forecast, by Test 8.5. Global Primary Immunodeficiency Diseases Market Analysis, by Test 8.6. Global Primary Immunodeficiency Diseases Market Attractiveness Analysis, by Test 9. Global Primary Immunodeficiency Diseases Market Analysis and Forecast, by Disease 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease 9.4. Global Primary Immunodeficiency Diseases Market Size (US$ Bn) Forecast, by Disease 9.5. Global Primary Immunodeficiency Diseases Market Analysis, by Disease 9.6. Global Primary Immunodeficiency Diseases Market Attractiveness Analysis, by Disease 10. Global Primary Immunodeficiency Diseases Market Analysis, by Region 10.1. Global Primary Immunodeficiency Diseases Market Value Share Analysis, by Region 10.2. Global Primary Immunodeficiency Diseases Market Size (US$ Bn) Forecast, by Region 10.3. Global Primary Immunodeficiency Diseases Market Attractiveness Analysis, by Region 11. North America Primary Immunodeficiency Diseases Market Analysis 11.1. Key Findings 11.2. North America Primary Immunodeficiency Diseases Market Overview 11.3. North America Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment 11.4. North America Primary Immunodeficiency Diseases Market Forecast, by Treatment 11.4.1. Immunoglobulin Replacement Therapy 11.4.2. Antibiotic Therapy 11.4.3. Stem cell and Gene Therapy 11.4.4. Others 11.5. North America Primary Immunodeficiency Diseases Market Value Share Analysis, by Test 11.6. North America Primary Immunodeficiency Diseases Market Forecast, by Test 11.6.1. Blood Test 11.6.2. Prenatal Testing 11.7. North America Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease 11.8. North America Primary Immunodeficiency Diseases Market Forecast, by Disease 11.8.1. Antibody Deficiency 11.8.2. Cellular Immunodeficiency 11.8.3. Innate Immune Disorder 11.9. North America Primary Immunodeficiency Diseases Market Value Share Analysis, by Country 11.10. North America Primary Immunodeficiency Diseases Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Primary Immunodeficiency Diseases Market Analysis, by Country 11.12. U.S. Primary Immunodeficiency Diseases Market Forecast, by Treatment 11.12.1. Immunoglobulin Replacement Therapy 11.12.2. Antibiotic Therapy 11.12.3. Stem cell and Gene Therapy 11.12.4. Others 11.13. U.S. Primary Immunodeficiency Diseases Market Forecast, by Test 11.13.1. Blood Test 11.13.2. Prenatal Testing 11.14. U.S. Primary Immunodeficiency Diseases Market Forecast, by Disease 11.14.1. Antibody Deficiency 11.14.2. Cellular Immunodeficiency 11.14.3. Innate Immune Disorder 11.15. Canada Primary Immunodeficiency Diseases Market Forecast, by Treatment 11.15.1. Immunoglobulin Replacement Therapy 11.15.2. Antibiotic Therapy 11.15.3. Stem cell and Gene Therapy 11.15.4. Others 11.16. Steel Canada Primary Immunodeficiency Diseases Market Forecast, by Test 11.16.1. Blood Test 11.16.2. Prenatal Testing 11.17. Canada Primary Immunodeficiency Diseases Market Forecast, by Disease 11.17.1. Antibody Deficiency 11.17.2. Cellular Immunodeficiency 11.17.3. Innate Immune Disorder 11.18. North America Primary Immunodeficiency Diseases Market Attractiveness Analysis 11.18.1. By Treatment 11.18.2. By Test 11.18.3. By Disease 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Primary Immunodeficiency Diseases Market Analysis 12.1. Key Findings 12.2. Europe Primary Immunodeficiency Diseases Market Overview 12.3. Europe Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment 12.4. Europe Primary Immunodeficiency Diseases Market Forecast, by Treatment 12.4.1. Immunoglobulin Replacement Therapy 12.4.2. Antibiotic Therapy 12.4.3. Stem cell and Gene Therapy 12.4.4. Others 12.5. Europe Primary Immunodeficiency Diseases Market Value Share Analysis, by Test 12.6. Europe Primary Immunodeficiency Diseases Market Forecast, by Test 12.6.1. Blood Test 12.6.2. Prenatal Testing 12.7. Europe Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease 12.8. Europe Primary Immunodeficiency Diseases Market Forecast, by Disease 12.8.1. Antibody Deficiency 12.8.2. Cellular Immunodeficiency 12.8.3. Innate Immune Disorder 12.9. Europe Primary Immunodeficiency Diseases Market Value Share Analysis, by Country 12.10. Europe Primary Immunodeficiency Diseases Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Primary Immunodeficiency Diseases Market Analysis, by Country 12.12. Germany Primary Immunodeficiency Diseases Market Forecast, by Treatment 12.12.1. Immunoglobulin Replacement Therapy 12.12.2. Antibiotic Therapy 12.12.3. Stem cell and Gene Therapy 12.12.4. Others 12.13. Germany Primary Immunodeficiency Diseases Market Forecast, by Test 12.13.1. Blood Test 12.13.2. Prenatal Testing 12.14. Germany Primary Immunodeficiency Diseases Market Forecast, by Disease 12.14.1. Antibody Deficiency 12.14.2. Cellular Immunodeficiency 12.14.3. Innate Immune Disorder 12.15. U.K. Primary Immunodeficiency Diseases Market Forecast, by Treatment 12.15.1. Immunoglobulin Replacement Therapy 12.15.2. Antibiotic Therapy 12.15.3. Stem cell and Gene Therapy 12.15.4. Others 12.16. U.K. Primary Immunodeficiency Diseases Market Forecast, by Test 12.16.1. Blood Test 12.16.2. Prenatal Testing 12.17. U.K. Primary Immunodeficiency Diseases Market Forecast, by Disease 12.17.1. Antibody Deficiency 12.17.2. Cellular Immunodeficiency 12.17.3. Innate Immune Disorder 12.18. France Primary Immunodeficiency Diseases Market Forecast, by Treatment 12.18.1. Immunoglobulin Replacement Therapy 12.18.2. Antibiotic Therapy 12.18.3. Stem cell and Gene Therapy 12.18.4. Others 12.19. France Primary Immunodeficiency Diseases Market Forecast, by Test 12.19.1. Blood Test 12.19.2. Prenatal Testing 12.20. France Primary Immunodeficiency Diseases Market Forecast, by Disease 12.20.1. Antibody Deficiency 12.20.2. Cellular Immunodeficiency 12.20.3. Innate Immune Disorder 12.21. Italy Primary Immunodeficiency Diseases Market Forecast, by Treatment 12.21.1. Immunoglobulin Replacement Therapy 12.21.2. Antibiotic Therapy 12.21.3. Stem cell and Gene Therapy 12.21.4. Others 12.22. Italy Primary Immunodeficiency Diseases Market Forecast, by Test 12.22.1. Blood Test 12.22.2. Prenatal Testing 12.23. Italy Primary Immunodeficiency Diseases Market Forecast, by Disease 12.23.1. Antibody Deficiency 12.23.2. Cellular Immunodeficiency 12.23.3. Innate Immune Disorder 12.24. Spain Primary Immunodeficiency Diseases Market Forecast, by Treatment 12.24.1. Immunoglobulin Replacement Therapy 12.24.2. Antibiotic Therapy 12.24.3. Stem cell and Gene Therapy 12.24.4. Others 12.25. Spain Primary Immunodeficiency Diseases Market Forecast, by Test 12.25.1. Blood Test 12.25.2. Prenatal Testing 12.26. Spain Primary Immunodeficiency Diseases Market Forecast, by Disease 12.26.1. Antibody Deficiency 12.26.2. Cellular Immunodeficiency 12.26.3. Innate Immune Disorder 12.27. Rest of Europe Primary Immunodeficiency Diseases Market Forecast, by Treatment 12.27.1. Immunoglobulin Replacement Therapy 12.27.2. Antibiotic Therapy 12.27.3. Stem cell and Gene Therapy 12.27.4. Others 12.28. Rest of Europe Primary Immunodeficiency Diseases Market Forecast, by Test 12.28.1. Blood Test 12.28.2. Prenatal Testing 12.29. Rest Of Europe Primary Immunodeficiency Diseases Market Forecast, by Disease 12.29.1. Antibody Deficiency 12.29.2. Cellular Immunodeficiency 12.29.3. Innate Immune Disorder 12.30. Europe Primary Immunodeficiency Diseases Market Attractiveness Analysis 12.30.1. By Treatment 12.30.2. By Test 12.30.3. By Disease 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Primary Immunodeficiency Diseases Market Analysis 13.1. Key Findings 13.2. Asia Pacific Primary Immunodeficiency Diseases Market Overview 13.3. Asia Pacific Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment 13.4. Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Treatment 13.4.1. Immunoglobulin Replacement Therapy 13.4.2. Antibiotic Therapy 13.4.3. Stem cell and Gene Therapy 13.4.4. Others 13.5. Asia Pacific Primary Immunodeficiency Diseases Market Value Share Analysis, by Test 13.6. Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Test 13.6.1. Blood Test 13.6.2. Prenatal Testing 13.7. Asia Pacific Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease 13.8. Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Disease 13.8.1. Antibody Deficiency 13.8.2. Cellular Immunodeficiency 13.8.3. Innate Immune Disorder 13.9. Asia Pacific Primary Immunodeficiency Diseases Market Value Share Analysis, by Country 13.10. Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Primary Immunodeficiency Diseases Market Analysis, by Country 13.12. China Primary Immunodeficiency Diseases Market Forecast, by Treatment 13.12.1. Immunoglobulin Replacement Therapy 13.12.2. Antibiotic Therapy 13.12.3. Stem cell and Gene Therapy 13.12.4. Others 13.13. China Primary Immunodeficiency Diseases Market Forecast, by Test 13.13.1. Blood Test 13.13.2. Prenatal Testing 13.14. China Primary Immunodeficiency Diseases Market Forecast, by Disease 13.14.1. Antibody Deficiency 13.14.2. Cellular Immunodeficiency 13.14.3. Innate Immune Disorder 13.15. India Primary Immunodeficiency Diseases Market Forecast, by Treatment 13.15.1. Immunoglobulin Replacement Therapy 13.15.2. Antibiotic Therapy 13.15.3. Stem cell and Gene Therapy 13.15.4. Others 13.16. India Primary Immunodeficiency Diseases Market Forecast, by Test 13.16.1. Blood Test 13.16.2. Prenatal Testing 13.17. India Primary Immunodeficiency Diseases Market Forecast, by Disease 13.17.1. Antibody Deficiency 13.17.2. Cellular Immunodeficiency 13.17.3. Innate Immune Disorder 13.18. Japan Primary Immunodeficiency Diseases Market Forecast, by Treatment 13.18.1. Immunoglobulin Replacement Therapy 13.18.2. Antibiotic Therapy 13.18.3. Stem cell and Gene Therapy 13.18.4. Others 13.19. Japan Primary Immunodeficiency Diseases Market Forecast, by Test 13.19.1. Blood Test 13.19.2. Prenatal Testing 13.20. Japan Primary Immunodeficiency Diseases Market Forecast, by Disease 13.20.1. Antibody Deficiency 13.20.2. Cellular Immunodeficiency 13.20.3. Innate Immune Disorder 13.21. ASEAN Primary Immunodeficiency Diseases Market Forecast, by Treatment 13.21.1. Immunoglobulin Replacement Therapy 13.21.2. Antibiotic Therapy 13.21.3. Stem cell and Gene Therapy 13.21.4. Others 13.22. ASEAN Primary Immunodeficiency Diseases Market Forecast, by Test 13.22.1. Blood Test 13.22.2. Prenatal Testing 13.23. ASEAN Primary Immunodeficiency Diseases Market Forecast, by Disease 13.23.1. Antibody Deficiency 13.23.2. Cellular Immunodeficiency 13.23.3. Innate Immune Disorder 13.24. Rest of Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Treatment 13.24.1. Immunoglobulin Replacement Therapy 13.24.2. Antibiotic Therapy 13.24.3. Stem cell and Gene Therapy 13.24.4. Others 13.25. Rest of Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Test 13.25.1. Blood Test 13.25.2. Prenatal Testing 13.26. Rest of Asia Pacific Primary Immunodeficiency Diseases Market Forecast, by Disease 13.26.1. Antibody Deficiency 13.26.2. Cellular Immunodeficiency 13.26.3. Innate Immune Disorder 13.27. Asia Pacific Primary Immunodeficiency Diseases Market Attractiveness Analysis 13.27.1. By Treatment 13.27.2. By Test 13.27.3. By Disease 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Primary Immunodeficiency Diseases Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Primary Immunodeficiency Diseases Market Overview 14.3. Middle East & Africa Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment 14.4. Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Treatment 14.4.1. Immunoglobulin Replacement Therapy 14.4.2. Antibiotic Therapy 14.4.3. Stem cell and Gene Therapy 14.4.4. Others 14.5. Middle East & Africa Primary Immunodeficiency Diseases Market Value Share Analysis, by Test 14.6. Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Test 14.6.1. Blood Test 14.6.2. Prenatal Testing 14.7. Middle East & Africa Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease 14.8. Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Disease 14.8.1. Antibody Deficiency 14.8.2. Cellular Immunodeficiency 14.8.3. Innate Immune Disorder 14.9. Middle East & Africa Primary Immunodeficiency Diseases Market Value Share Analysis, by Country 14.10. Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Primary Immunodeficiency Diseases Market Analysis, by Country 14.12. GCC Primary Immunodeficiency Diseases Market Forecast, by Treatment 14.12.1. Immunoglobulin Replacement Therapy 14.12.2. Antibiotic Therapy 14.12.3. Stem cell and Gene Therapy 14.12.4. Others 14.13. GCC Primary Immunodeficiency Diseases Market Forecast, by Test 14.13.1. Blood Test 14.13.2. Prenatal Testing 14.14. GCC Primary Immunodeficiency Diseases Market Forecast, by Disease 14.14.1. Antibody Deficiency 14.14.2. Cellular Immunodeficiency 14.14.3. Innate Immune Disorder 14.15. South Africa Primary Immunodeficiency Diseases Market Forecast, by Treatment 14.15.1. Immunoglobulin Replacement Therapy 14.15.2. Antibiotic Therapy 14.15.3. Stem cell and Gene Therapy 14.15.4. Others 14.16. South Africa Primary Immunodeficiency Diseases Market Forecast, by Test 14.16.1. Blood Test 14.16.2. Prenatal Testing 14.17. South Africa Primary Immunodeficiency Diseases Market Forecast, by Disease 14.17.1. Antibody Deficiency 14.17.2. Cellular Immunodeficiency 14.17.3. Innate Immune Disorder 14.18. Rest of Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Treatment 14.18.1. Immunoglobulin Replacement Therapy 14.18.2. Antibiotic Therapy 14.18.3. Stem cell and Gene Therapy 14.18.4. Others 14.19. Rest of Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Test 14.19.1. Blood Test 14.19.2. Prenatal Testing 14.20. Rest of Middle East & Africa Primary Immunodeficiency Diseases Market Forecast, by Disease 14.20.1. Antibody Deficiency 14.20.2. Cellular Immunodeficiency 14.20.3. Innate Immune Disorder 14.21. Middle East & Africa Primary Immunodeficiency Diseases Market Attractiveness Analysis 14.21.1. By Treatment 14.21.2. By Test 14.21.3. By Disease 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Primary Immunodeficiency Diseases Market Analysis 15.1. Key Findings 15.2. South America Primary Immunodeficiency Diseases Market Overview 15.3. South America Primary Immunodeficiency Diseases Market Value Share Analysis, by Treatment 15.4. South America Primary Immunodeficiency Diseases Market Forecast, by Treatment 15.4.1. Immunoglobulin Replacement Therapy 15.4.2. Antibiotic Therapy 15.4.3. Stem cell and Gene Therapy 15.4.4. Others 15.5. South America Primary Immunodeficiency Diseases Market Value Share Analysis, by Test 15.6. South America Primary Immunodeficiency Diseases Market Forecast, by Test 15.6.1. Blood Test 15.6.2. Prenatal Testing 15.7. South America Primary Immunodeficiency Diseases Market Value Share Analysis, by Disease 15.8. South America Primary Immunodeficiency Diseases Market Forecast, by Disease 15.8.1. Antibody Deficiency 15.8.2. Cellular Immunodeficiency 15.8.3. Innate Immune Disorder 15.9. South America Primary Immunodeficiency Diseases Market Value Share Analysis, by Country 15.10. South America Primary Immunodeficiency Diseases Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Primary Immunodeficiency Diseases Market Analysis, by Country 15.12. Brazil Primary Immunodeficiency Diseases Market Forecast, by Treatment 15.12.1. Immunoglobulin Replacement Therapy 15.12.2. Antibiotic Therapy 15.12.3. Stem cell and Gene Therapy 15.12.4. Others 15.13. Brazil Primary Immunodeficiency Diseases Market Forecast, by Test 15.13.1. Blood Test 15.13.2. Prenatal Testing 15.14. Brazil Primary Immunodeficiency Diseases Market Forecast, by Disease 15.14.1. Antibody Deficiency 15.14.2. Cellular Immunodeficiency 15.14.3. Innate Immune Disorder 15.15. Mexico Primary Immunodeficiency Diseases Market Forecast, by Treatment 15.15.1. Immunoglobulin Replacement Therapy 15.15.2. Antibiotic Therapy 15.15.3. Stem cell and Gene Therapy 15.15.4. Others 15.16. Mexico Primary Immunodeficiency Diseases Market Forecast, by Test 15.16.1. Blood Test 15.16.2. Prenatal Testing 15.17. Mexico Primary Immunodeficiency Diseases Market Forecast, by Disease 15.17.1. Antibody Deficiency 15.17.2. Cellular Immunodeficiency 15.17.3. Innate Immune Disorder 15.18. Rest of South America Primary Immunodeficiency Diseases Market Forecast, by Treatment 15.18.1. Immunoglobulin Replacement Therapy 15.18.2. Antibiotic Therapy 15.18.3. Stem cell and Gene Therapy 15.18.4. Others 15.19. Rest of South America Primary Immunodeficiency Diseases Market Forecast, by Test 15.19.1. Blood Test 15.19.2. Prenatal Testing 15.20. Rest of South America Primary Immunodeficiency Diseases Market Forecast, by Disease 15.20.1. Antibody Deficiency 15.20.2. Cellular Immunodeficiency 15.20.3. Innate Immune Disorder 15.21. South America Primary Immunodeficiency Diseases Market Attractiveness Analysis 15.21.1. By Treatment 15.21.2. By Test 15.21.3. By Disease 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Baxter International, Inc., 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Biotest AG, 16.3.3. CSL Behring LLC, 16.3.4. Bio Products Laboratory Ltd., 16.3.5. Kedrion S.p.A., 16.3.6. LFB S.A., 16.3.7. Octapharma AG 16.3.8. Grifols S.A 16.3.9. Abbott, 16.3.10. ADMA Biologics, 16.3.11. Astellas, 16.3.12. AstraZeneca, 16.3.13. Bayer, 16.3.14. Biocon, 16.3.15. Bristol-Myers Squibb, 16.3.16. BDI Pharma, 16.3.17. Bharat Serums and Vaccines, 16.3.18. Eli Lilly, 16.3.19. GlaxoSmithKline, 16.3.20. Hualan Biological Engineering, 16.3.21. Kedrion Biopharma, 16.3.22. Lupin Pharmaceuticals, 17. Primary Key Insights

Global Primary Immunodeficiency Diseases Market

Choose License Type